TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
陳俊賓Chen, Chun-Bing
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
-
chunbing.chen@gmail.com
發表文獻
48筆
41
Lai YC, Chang WC, Chen CB, Wang CL, Lin YF, Ho MM, Cheng CY, Huang PW, Hsu CW and Lin G. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment. Acta Radiol. 2019 Nov 18:284185119887588. (SCI, IF=1.99, Radiology, Nuclear medicine & Medical Imaging 114/136=83.8%)
42
Lu KL, Wu MY, Wang CH, Wang CW, Hung SI, Chung WH, Chen CB*. The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus. Cells. 2019 Oct 8;8(10). (SCI, IF=7.666, Cell Biology 51/194=26.3%)
43
Pan RY, Chu MT, Wang CW, Lee YS, Lemonnier F, Aaron W. Michels, Schutte R, David A. Ostrov, Chen CB, Phillips EJ, Mallal SA, Mockenhaupt M, Bellón T , Tassaneeyakul W, White KD, Roujeau JC, Chung WH, Hung SI. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nat Commun. 2019 Aug 8;10(1):3569. (SCI, IF=17.694, Multidisplinary Sciences 6/73=8.2%)
44
Mockenhaupt M, Wang CW, Hung SI, Sekula P, Schmidt AH, Pan RY, Chen CB, Dunant A, Gouvello SL, Schumacher M, LaurenceVA, Bellon T, Sylvia H. Kardaun, Jan YS, Chung WH, Roujeau JC, RegiSCAR group. HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. Allergy. 2019 Nov;74(11):2227-2230. (SCI, IF=14.71, Allergy 1/27=3.7%) (Immunology15/161=9.3%)
45
Chen CH, Chen CB, Chang CJ, Lin YJ, Wang CW, Chi CC, Lu CW, Chen WT, Pan RY, Su SC, Hsu LA, Chang YC, Yu KH, Jan YJ Wu, Lin KM, Hung SI, Chen SM, Chung WH. Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population-Based Cohort Study and Meta-Analysis. Clin Pharmacol Ther. 2019 Aug;106(2):391-401. (SCI, IF=6.903, Pharmacology & Pharmacy 33/279=11.8%)
46
Goldman JL, Chung WH, Lee BR, Chen CB, Lu CW, Hoetzenecker W, Micheletti R, Yasuda SU, Mariolis DJ, Shear NH, Struewing JP, Pirmohamed M. Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. Eur J Clin Pharmacol. 2019 Aug;75(8):1135-1141. (SCI, IF=3.064, Pharmacology & Pharmacy 174/279=62.4%)
47
Tsai YG, Liou JH, Hung SI, Chen CB, Chiu TM, Wang CW, Chung WH. Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptom. J Invest Dermatol. 2019 Aug;139(8):1722-1731. (SCI, IF=7.59, Dermatology 5/69=7.2%)
48
Wang YH, Chen CB*, Tassaneeyakul W, Saito Y, Choon SE, Lee HY, Chang MM, Roa FD, Wu CW, Zhang J, Nakkam N, Konyoung P, Yoshimi OU, Cheung ChristinaMT, Huang JW, Ji C, Cheng B, Hui Rosaline CY, Chu CY, Chen YJ, Wu CY, Hsu CK, Chiu TM, Huang YH, Lu CW, Yang CY, Lin YT, Ho HC, Lin JY, Yang CH, Chang YC, Su SC, Wang CW, Fan WL, Hung SI, Chung WH; for the Asian Severe Cutaneous Adverse Reaction Consortium. The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: the Major Drug Causality and Comparison to the USA FDA Label. Clinical Pharmacology & Therapeutics 2019 Jan;105(1):112-120. (SCI, IF=6.903, Pharmacology & Pharmacy 33/279=11.8%) (Co-first author)
